CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
Androgen Suppression +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03570827
NCT03570827Phase 2Completed

A Phase II Trial of Hypofractionated Radiation Therapy for Prostate Cancer With High Risk Features After Radical Prostatectomy

Mayo Clinic·interventional·Posted Jun 27, 2018·Updated May 26, 2026

In Brief

A Phase 2 clinical trial evaluating Androgen Suppression, Hypofractionated Radiation Therapy, and 2 other interventions for Prostate Adenocarcinoma and 5 related conditions. Completed, enrolled 53 participants across 2 sites.

Detailed Summary

This phase II trial studies how well hypofractionated radiation therapy works in treating participants with prostate cancer high-risk features following radical prostatectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Study Details

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 27, 2018
Enrollment StartMay 14, 2018
Primary CompletionMay 15, 2025
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 8.0 years ago

Interventions

Androgen Suppressiondrug

Given androgen suppression therapy

Hypofractionated Radiation Therapyradiation

Undergo hypofractionated radiation therapy

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies